EFFICACY OF MIRABEGRON ADD-ON THERAPY TO SILODOSIN FOR THE TREATMENT OF PERSISTENT STORAGE SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Main Article Content
Keywords
Benign prostatic hyperplasia, Lower urinary tract symptoms, International prostate symptom score, Silodosin, Mirabegron
Abstract
Introduction: BPH associated lower urinary symptoms (LUTS) represent one of the most common bothersome condition in day to day urological practice and having negative impact on patient’s quality of life (QoL). Silodosin alone fails to alleviate moderate to severe storage symptoms and thus requiring additional therapeutic approach. The present study was aimed to evaluate the efficacy of Mirabegron addition in BPH patients on silodosin complaining of persistent storage LUTS.
Materials & methods: A total no of 130 patients of BPH on silodosin 8 mg with persistent storage LUTS who had attended urology OPD, Regional Institute of Medical Sciences (RIMS), Imphal were randomized into two groups and prospectively evaluated for 8 weeks. Group-A continued to use silodosin 8 mg only whereas mirabegron 25 mg was added with silodosin in group-B and statistically evaluated.
Results: After completion of 8 weeks group-B showed statistically significant improvement in respect to total IPSS (p-0.04); IPSS storage (p-0.002) and QoL (p- 0.006) score. However no statistically significant difference was noted in term of Q-max and residual urine volume measurement between both the groups.
Conclusion: Mirabegron, a potent B3 adrenoreceptor agonist improves compliance by relaxation of bladder smooth muscle. Add-on therapy is more effective than monotherapy for improvement of quality of life improvement and alleviation of persistent storage symptoms in BPH patients.
References
2. Zhang AY, Xu X. Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature. SAGE Open Nurs. 2018 Dec 26;4:2377960818811773.
3. Jindan L, Xiao W, Liping X. Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review. Drug Des Devel Ther. 2022 Aug 26;16:2861-2884.
4. Kang TW, Chung HC. Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy. Ther Adv Urol. 2020 Dec 18;12:1756287220974130.
5. Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther. 2017 Feb 20;11:463-467.
6. Kuo YC, Kuo HC. Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients. Tzu Chi Med J. 2021 Dec 10;35(1):62-68.
7. Kwon SY, Park DJ, Seo YJ, Lee KS. Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study. Investig Clin Urol. 2020 Jul;61(4):419-424.
8. Saygisever FK, Faikoglu G, Ozcan FO, Berk B. The efficacy and safety of silodosin-a review of literature. Pharm Pharmacol Int J. 2021;9(6):249‒256.
9. Yamanishi T, Mizuno T, Kamai T, Yoshida K, Sakakibara R, Uchiyama T. Management of benign prostatic hyperplasia with silodosin. Open Access J Urol. 2009 Aug 20;1:1-7.
10. Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014;2(2):43-9.
11. Gacci M, Sebastianelli A, Spatafora P, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Therapeutic Advances in Urology. 2018;10(2):79-92.
12. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012 Dec;110(11):1767-74.
13. Tyagi P, Tyagi V. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs. 2010 Oct;13(10):713-22.
14. Matsukawa Y, Takai S, Majima T, Funahashi Y, Sassa N, Kato M, Yamamoto T, Gotoh M. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies. Neurourol Urodyn. 2019 Mar;38(3):941-949.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Khumukcham Somarendra
Assistant Professor, Department of Urology, Regional Institute of Medical Sciences, Imphal, Manipur, India
Dr.Bijit Lodh
Assistant Professor, Department of Urology, Agartala Government Medical College, Agartala, Tripura, India